GSK Battles Back With Strong 2Q Results, Says 2012 Will Be A Transformational Year
This article was originally published in The Pink Sheet Daily
After hitting a low point, GlaxoSmithKline believes its second quarter results reflect a turnaround for the company and the progress the company has made in strengthening it portfolio.
You may also be interested in...
The indication is notable for what it does not contain, which is language specifically excluding African Americans or patients with severe active lupus nephritis or severe central nervous system lupus.
In deciding to keep GlaxoSmithKline PLC’s Avandia on the market, while also heavily restricting its use, FDA Center for Drug Evaluation and Research Director Janet Woodcock split the difference between opposing recommendations from the Office of New Drugs and Office of Surveillance and Epidemiology.
GSK’s Promacta Effective In Raising Platelet Count In HCV-Associated Thrombocytopenia, Phase II Data Show
Results published in the New England Journal of Medicine demonstrate 95 percent of hepatitis C patients with thrombocytopenia taking 75 mg dose of eltrombopag once daily had elevated platelet counts.